Related Experiment Video

Updated: Dec 25, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.2K

PDE4 subtypes in cancer

Samuel Hsien Lai1, Guston Zervoudakis1, Jesse Chou1

  • 1Department of Biomedical Sciences, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.

Oncogene
|March 24, 2020
PubMed

Insights

Cyclic nucleotide phosphodiesterases (PDE) regulate cellular signals. This review highlights the PDE4 family

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Cyclic nucleotide phosphodiesterases (PDE) are crucial enzymes that regulate intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
  • Specific PDE families, such as PDE4, play significant roles in cellular signaling pathways relevant to various physiological and pathological processes.
  • Dysregulation of PDE activity has been implicated in numerous diseases, prompting investigation into their therapeutic potential.

Purpose of the Study:

  • To systematically review and summarize the existing literature on the role of the PDE4 subfamily of phosphodiesterases in malignancy.
  • To investigate the specific PDE4 isoforms (PDE4A, PDE4B, PDE4C, and PDE4D) and their association with different cancer types.
  • To establish a case for PDE4 subtypes as potential therapeutic targets in cancer treatment.

Main Methods:

  • Systematic literature review and analysis of studies investigating PDE4 isoforms in various malignancies.
  • Comparative analysis of evidence linking PDE4A, PDE4B, PDE4C, and PDE4D to cancer development and progression.
  • Identification of common signaling themes and pathways modulated by PDE4 subtypes across different cancer types.

Main Results:

  • Evidence associates PDE4 isoforms with several cancer types, including hematologic malignancies and lung cancers.
  • The review identifies specific PDE4 subtypes and their functional roles in the context of malignancy.
  • Common signaling pathways influenced by PDE4 subtypes in cancer are highlighted.

Conclusions:

  • The PDE4 subfamily of phosphodiesterases emerges as a significant player in the development and progression of various cancers.
  • PDE4 subtypes represent a promising avenue for novel cancer therapeutic strategies.
  • Further research into PDE4-targeted therapies could lead to effective treatments for malignancies.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.5K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.0K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K